STOCKS TELEGRAPH

Author: ST Staff

  • Mind Medicine (MindMed) Inc. (MNMD) is going up. Why?

    At last check, the Mind Medicine stock is up 3.16 percent in premarket trading and could continue to rise as researchers look at the effects of LSD on anxiety, pain, and adult ADHD. If the company continues to succeed, it might get access to multibillion-dollar mental health markets, such as the $4.7 billion anxiety industry and the $9.5 billion ADHD market.

    The R(-)-MDMA Program by MindMed adds to the company’s drug development pipeline

    The initiation of a program to produce R(-)-MDMA for the treatment of social anxiety and functioning in diagnoses such as Autism Spectrum Disorder has expanded the pipeline of a major biotech business developing psychedelic-inspired treatments (ASD). This program represents a significant expansion and diversity of MindMed’s pipeline, and it advances the company’s aim of developing novel solutions that help patients and meet unmet medical needs.

    ASD is characterized by social anxiety and deficits in social functioning, and it affects about 2% of people in the United States. There are currently no authorized medicines for ASD’s basic symptoms, and there is a substantial unmet need for innovative medications to help persons with the disorder. The expense of ASD is expected to reach $461 billion in the United States by 2025, underscoring the need for and possibility for innovative therapies. According to the National Institute of Mental Health, roughly 12% of the general population in the United States suffers with Social Anxiety Disorder at some point in their lives.

    MDMA, a racemic combination of two physically distinct stereoisomers, R(-) and S(+), is being developed for the treatment of Post-Traumatic Stress Disorder (PTSD), and has shown statistically significant favorable outcomes in a crucial Phase 3 experiment. In addition, participants with ASD demonstrated strong and statistically significant improvements in social anxiety and functioning after receiving short-term MDMA treatment in a pilot clinical experiment.Preclinical data suggests that the R(-) enantiomer of MDMA retains the acute pro-social and empathogenic advantages of racemic MDMA while exhibiting fewer symptoms of stimulant action, neurotoxicity, hyperthermia, and abuse liability. This favorable profile suggests that R(-)-MDMA could be used for purposes other than racemic MDMA, such as novel, more accessible delivery modes and repeat dosing.

    In terms of safety, the business has high confidence in the R(-) enantiomer, owing to its positive preclinical pharmacology and the amount of prior human dosing of the racemic combination, which provides valuable insight into R(-)-MDMA’s projected safety and tolerability. MindMed intends to progress its R(-)-MDMA development program in the United States and the European Union, with the first clinical trials expected to begin in 2022. MindMed and the Liechti Lab at University Hospital Basel (UHB) propose to start a comparative pharmacokinetics and pharmacodynamic clinical trial of R(-)-MDMA, S(+)-MDMA, and R/S-MDMA in 2022 as a major initial investigation.

    This double-blind, placebo-controlled crossover trial in healthy volunteers will investigate differences in acute and long-term effects of MDMA and its two enantiomers, and will give crucial information on the best treatment paradigm for R(-)-MDMA.

    Q2 Financial Results 2021 

    As of June 30, 2021, the company’s total assets were $194 million, including $157 million in cash. For the quarter ended June 30, 2021, net cash used in operating activities was $12 million. For the quarter ending June 30, 2021, there was a net and comprehensive loss of $36 million.

    Sphere Health and MindMed have announced a strategic research collaboration 

    Sphere Health, a physician-founded employee benefits provider focused on treatments for people with severe mental illness, has agreed to collaborate with a leading biotech company developing psychedelic-inspired therapies to collect and analyze multimodal data in order to improve the understanding of a variety of biomarkers associated with mental illnesses such as anxiety and affective disorders.

    MindMed and Sphere Health are collaborating on MM061302, a project that will employ existing consumer technologies to create a robust data collection that can be used to generate more accurate machine learning techniques to detect biomarkers that are associated with and predict anxiety and depression symptoms. The findings of the study can be utilized to better understand mental health diseases and may aid in the development of future digital technologies to help both people with mood disorders and the professionals who care for them.

    Study data can also be de-identified and linked at the subject-level to other data sets, preserving patient privacy while providing additional insights based on real-world data, thanks to a collaboration with MindMed’s colleague Datavant.

  • CohBar Inc (CWBR) Stock Declines, Here’s What You Need To Know

    Tthe shares of CohBar Inc (CWBR) was down 35.12% in premarket trading and is down -$0.32 from its previous closing price of $0.90. CWBR stock has lost 34.83 percent in the last year. Over the last year, CWBR has lost -$0.29 per share.

    On November 15, 2021, CohBar Inc will release its financial results for the third quarter of 2021 and provide an update on its business. After the market closes on Monday, November 15, 2021, the firm will reveal its third quarter financial results. On the same day, management will have a conference call to offer an update on the company’s operations at 5:00 p.m. ET (2:00 p.m. PT).

    From 8:00 p.m. Eastern Time on November 15, 2021, through 11:59 p.m. Eastern Time on December 6, 2021, an audio recording of the conference call will be accessible.

    Second Quarter 2021 Results

    CohBar has $13.8 million in cash and investments as of June 30, 2021, compared to $21 million as of December 31, 2020. For the quarter ended June 30, 2021, the cash burn was around $4.6 million. For the three months ended June 30, 2021, research and development costs were $2.6 million, up from $1.5 million in the prior year quarter. The increase in R&D expenses was primarily due to investments in the company’s research programs focused on the continued development of its peptides, as well as an increase in clinical trial costs due to the timing of those expenses, which was partially offset by a decrease in stock-based compensation costs.

    For the three months ending June 30, 2021, general and administrative expenses were $2.6 million, up from $1.4 million the year before. Higher salary and stock-based compensation costs, as well as rising D&O insurance premiums, drove up general and administrative expenses.

    Net loss was $5.2 million, or $0.08 per basic and diluted share, for the three months ended June 30, 2021, which includes $1.0 million in non-cash expenses. Net loss was $4.1 million, or $0.09 per basic and diluted share, for the three months ended June 30, 2020, which includes $1.8 million in non-cash expenses.

    Despite the fact that CohBar, Inc. (CWBR) has lost US$647k in value, insiders who invested last year have realized gains of roughly US$8.6k thus far.

    CohBar, Inc. (CWBR) shareholders who bought the company less than a year ago are unlikely to notice the firm’s recent 25% decrease. After taking into account the recent loss, the shares they purchased for US$119k are now worth US$127k, indicating a good return on their investment.

    Insiders at CohBar have been buying rather than selling shares during the last year. The average purchase price was approximately US$0.63. These transactions demonstrate that insiders are confident enough in the company to put their own money in it, albeit at a significantly lower price than it has been recently.

  • Why are Sundial Growers Inc (SNDL) stocks trading at such a low level today?

    As of Premarket trading, Sundial Growers Inc (SNDL) was trading at $0.66, up $0.01 or 1.16 percent from its previous closing price of $0.65. So far today, the stock has traded between $0.65 and $0.67.

    Sundial Inc. announced Financial and Operational Results for the Third Quarter of 2021

     

    In the third quarter of 2021, net earnings were $11.3 million, compared to a loss of $71.4 million the previous year. In the third quarter of 2021, adjusted EBITDA was $10.5 million, compared to a loss of $4.4 million in the third quarter of 2020. For the third quarter of 2021, net revenue from Cannabis divisions was $14.4 million, up 57 percent from the second quarter of 2021 and up 12 percent from the third quarter of 2020.

    Cannabis divisions had a $1.8 million gross margin, including a $1.9 million loss from cannabis cultivation and production, compared to a $19.5 million loss in the third quarter of 2020. The third quarter of 2021 saw $3.3 million in investment and fee revenue, $6.0 million in realized gains on marketable securities, and $9.9 million in Sundial’s share of profit from equity accounted investees, compared to Nil in the third quarter of the previous year, which preceded the start of these activities.

    At September 30, 2021, the company had $1.1 billion in cash, marketable securities, and long-term investments, compared to $1.2 billion on November 9, 2021, with $571 million in unrestricted cash and no outstanding debt. Inner Spirit was acquired on July 20, 2021, and Alcanna Inc. (“Alcanna’), Canada’s largest private liquor retailer with 171 stores, was acquired on October 7, 2021, following the end of the third quarter.

    Sundial Growers Benefit from Liquor Business Acquisition 

    Sundial put 22 million Canadian dollars into Indiva, a cannabis food company (NDVAF). Half of the 22 million CAD was invested as equity, while the other half was a term loan that Indiva would repay with interest. Sundial also revised the transaction this month, giving Indiva an additional 8.5 million CAD.

    The interest rate on the loan was increased from 9% to 15% under the revised agreement.That adds a lot of value to Sundial’s offer. Furthermore, “100% of accrued interest is payable in cash and accrued on a monthly basis,” according to the agreement.

    With all of this, Sundial is on track to produce monthly interest revenue of approximately 246,899 CAD, or $197,519 in US dollars. Of course, Indiva’s ability to repay the loan with interest is a factor, so Sundial investors should keep an eye on the situation.

    Stock and Future Margins for SNDL

    Over 170 cannabis businesses and 171 booze stores will be owned outright or controlled by Sundial across Canada. That places it firmly in the upper echelon of Canadian retail, let alone cannabis or alcohol.

    One of the benefits of the purchase, according to Sundial’s management, will be a $15 million increase in EBITDA (earnings before interest and taxes) due to synergies discovered between the two companies. In the cannabis market, every dollar of earnings counts, so $15 million is significant.

  • Progenity, Inc. (PROG) stock gains, here’s what you should know

    Progenity, Inc. (PROG) stock gains, here’s what you should know

    Progenity, Inc. (PROG) stock gained value in pre-market after they announced the financial statement of their 3rd quarter on 10 November. Progenity, Inc. (PROG) stock saw 4.38% increase reaching to a value of $3.10 in premarket.  The volume of the stock traded was 111.36 Million.

    Milestones achieved in the 3rd quarter of the current financial year:

    • Inclusion of significant patents that will help protecting the therapeutic delivery of the company.
    • This year Progenity, Inc. (PROG) implemented cost reducing measure. These measures are expected to save $145 million annually.
    • Partnership with a large pharmaceutical company that will to evaluate OBDS that is currently under developing.

    Financial Highlights:

    • Revenue for the 3rd quarter was $9.6 million out of which $9.4 million was generated from the operations which were discontinued by the company for some reasons.
    • Expenses were reduced to $30.7 million as compared to the expenses of 2nd quarter which were $36.1 million.
    • Net loss for the 3rd quarter was $43.7 million. Net loss in the 2nd quarter was $78.5 million.
    • Progenity, Inc. (PROG) shares have lost 33.35 in value since the beginning of the year.

    Impact of financial statement announcement on the stock price:

    The Progenity, Inc. (PROG) announced its 3rd quarter financial statement on 10 November 2021. Before the announcement of its financial statements the estimated revision trends for Progenity, Inc. (PROG) were mixed. The impact of the proposed revised estimation as per the company’s just released financial statement. The stock is expected to be in line with the market in the near future.

    What next for the Progenity, Inc. (PROG) stock ?

    Although Progenity, Inc. (PROG) did not performed well in this year. Is this stock still worth investing? Well there is no absolute answer to this question but one thing that investors should look upon is that to keep track of its quarterly earnings. That is one variable for the estimation. The outlook of the Industry has also the huge impact on the share price of a company.

    Conclusion:

    Despite for its unstable trend in the market, the financial report of the Progenity, Inc. (PROG)reveals that the company is planning to expand its operations. Progenity, Inc. (PROG) have managed to half the loss as per the previous quarter, which shows that Progenity, Inc. (PROG) is practically implementing to reduce the expenses. They 4 new patents will help them improve and keep their technology up to date.

  • Reasons of Medicenna Therapeutics Corp. (MDNA) downfall:

    Medicenna Therapeutics Corp. (MDNA) stock closed at 2.56 CAD as per the data of 12 November 2021. The volume of shares traded was 72.57K. There was no significant change in the price of share at the closing time and one day before of the trading price. Let’s dig deep into the information.

    Financial highlights of Medicenna Therapeutics Corp. (MDNA):

    • There renevue of 2021 and 2020 was zero.
    • The company did nothing in terms of sales. In both the financial years the company faced major losses.
    • Spending on research and development almost doubled. In 2020 they were $4,124 and in 2021 they were $8,649.

    Reasons of zero revenue:

    Medicenna Therapeutics Corp. (MDNA) does not provide any specific reasons for its zero revenue for continuously 2 years. They are very discrete abouot this information at the moment. But what onething it shows that is significant in the financial statement of Medicenna Therapeutics Corp. (MDNA) is that there Research and Development spending have almost doubled. The company is trying to experiment on many projects which are in pipeline. It could not be said with complete surety that it will bring a positive or negative change but it the Medicenna Therapeutics Corp. (MDNA) is working on something at the moment.

    Financial Highlights announced in 2021 financial statements:

    • Zero revenue
    • Medicenna had cash, cash equivalents, and marketable securities worth of $26.7 million at the time period of September 30, 2021. These funds were sufficient enough for the Company to execute its current planned spending through the end of calendar 2022 based on its recent plans.
    • Net loss for the quarter ended September 30, 2021, was $8.2 millioncompared to a loss of $3.8 millionfor the quarter ended on 30 September, 2020. The increase in net loss for the quarter ended September 30, 2021 compared with the quarter ended September 30, 2020 was mainly a result of increased R&D expenditures.

    Conclusion:

    The stock price of Medicenna Therapeutics Corp. (MDNA) is constantly going downwards. There revenues are zero for the consecutive 2 years. There press release did not announce any information in the recent past that will have a significant effect on the share price of its company. There is no financial data of the company which allows the financial analysts to forecast the growth rate with respect to its previous performances and upcoming trends.

  • Is Bit Brother Limited (BTB) the next stock for the investor to consider?

    Bit Brother Limited (BTB) stock surged in the after-market. Bit Brother Limited (BTB) stock increased by 57.36% and reached at $4.17 at the current time of this writing. The trading value of the stock traded was 4.12 million. In the previous trading session the stock closed at $2.00.

    Why their stock raised after facing huge downfall?

    After facing a significant loss in the revenue, the company is trying really hard to regain its strength. Its share price is increasing due to very important reason. The reason is Bit Brother Limited (BTB) is focusing on the aspect to carry out the business in cryptocurrency and blockchain industry. The company’s US subsidiary had recently obtained license of money services business by the name of Bit Brother New York. This license will allow them to perform operations as foreign exchange dealer, money transfer platform and money order seller.

    Financial overview of Bit Brother Limited (BTB):

    • The earning of Bit Brother Limited (BTB) increased 27.3% per year.
    • Their acceleration of growth is currently unable to forecast as for the last 5 years the company is unprofitable.
    • Bit Brother Limited (BTB) is right now at the moment unprofitable but they managed to reduce their debts by 27.3%.
    • Bit Brother Limited (BTB) has no debt as compared to the previous 5 years. At that time its debt to equity ratio was around 130%.

    What next?

    To analyze the future growth of Bit Brother Limited (BTB) is quite difficult at the moment because Bit Brother Limited (BTB) has not provided enough information regarding its data to forecast its growth by analyzing its financial data.

    Although their stock has been very volatile in the past and that was for the obvious reasons that they were miserably failing to achieve their revenue goals and was losing interest of the investors. But for the past couple of months its stock is rising and the trend is going in upward trajectory.

    Conclusion:

    Despite of the fact that its stock has been really volatile in the past, this year’s decision of going to enter the money services business in crypto currency and blockchain could bring significant results for the company. This could really turn out to be a game changer for the Bit Brother Limited (BTB) which could be seen in the upcoming year’s financial statements.

  • Will the Xponential Fitness Inc. (XPOF) stock continue its momentum?

    Will the Xponential Fitness Inc. (XPOF) stock continue its momentum?

    Shares of Xponential Fitness Inc. (XPOF) were seen in upward trajectory today in Pre-market after announcing the results of the Financial Statements of their Third Quarter. XPOF shares went up by 15.51% to reach $22.56, which is their highest after the decline which started in July. In the previous trading session the stocks were closed at $18.92.

    XPOF announced a partnership with Fitness International LLC:

    On 4rth November, 2021 Xponential Fitness Inc. (XPOF) announced that they are partnering with Fitness International LLC. The purpose of this partnership is to open various Xponential brands studios, e.g Club Pilates and Pure Barre, at City Sports Club and LA Fitness locations. The agreement says that it will develop atleast 350 franchised location over the course of 5 years in order to add Xponential Brands at more than 500 Fitness International locations.

    Effect of Xponential Fitness Inc. (XPOF) partnership with Fitness International LLC:

    With this joint venture, Xponential Fitness will expand into the new market segment. This will help them to increase their market and gain new customers through Fitness International 500 locations. This year Xponential Fitness sold 248 franchise licenses and opened 68 new studios.

    Financial Standings of Xponential Fitness Inc. 3rd quarter:

    • Increase in the revenue which was 60% more than the previous year’s same quarter. It increased $15.3 million making a total of $40.9 million.
    • North American system-wide sales increase by 93% from the previous 3rd quarter.
    • Adjusted EBITDAof $6.8 million which was $1.5 million as compared to the 3rd quarter of 2020.
    • Announced a net loss of $8.9 million as compared to last year $1.9 million.
    • Announced adjusted EBITDA of $6.8 million. Last year in the same quarter it was $1.5 million.

    Conclusion:

    Although Xponential Fitness Inc saw a major decline in the history of its share price. It went down as low as $10.15. But they bounced back and are at $19.53 in the Pre-market. This major development of partnering with Fitness International has a very positive effect on its stock. As it’s a long-term project of 5 years, its positive effect on the stock of Xponential Fitness Inc. would be seen over the course of this time.

  • Reasons why Altimeter Growth Corp. (AGC) stock at all time high

    Reasons why Altimeter Growth Corp. (AGC) stock at all time high

    Shares of Altimeter Growth Corp. (AGC) skyrocketed today in the Pre-market after Grab reports Third Quarter 2021 results. AGC shares went up by 12.53% to reach an all-time high of $17.06 in the Pre-market. In the previous trading session, the stock was closed at $15.16.

    What does Altimeter Growth Corp. (AGC) stock do?

    Altimeter Growth Corp. (AGC) is a leading technology-based investment company which serves and helps entrepreneurs and companies to build extraordinary companies and expand their market share and guide them through every stage of growth. Altimeter Growth Corp. (AGC) helps companies to go public and be there as an expert for the long-term to manage every kind of venture and public funds.

    On April 23, 2021, Grab, a leading superapp announced to go public with the partnership of Altimeter Growth Corp. (AGC). Both the companies say in the upcoming months their securities will be traded in NASDAQ under the ticker symbol “GRAB”.

    Partnership of GRAB with LAZADA in Singapore:

    On 02 November 2021 Grab a leading superapp announced partnership with Lazada. It will make Lazada Sellers provide same-day delivery services to its customers in Singapore through GrabExpress. The two companies are expanding their partnership after they had a similar partnership model in Indonesia and Malaysia. This will help Grab to increase its revenue from deliveries as it saw a growth of 58% in this quarter.

    Effect of Partnership of Grab and Lazada on Altimeter Growth Corp. (AGC) stock?

    This is the third time Lazada and Grab are partnering together. This will help Grab to enter a new market and get a fair amount of market share with its already existing partner. Their experience in in-time delivery services will create a good image for Lazada which will ultimately benefit Grab in terms of revenue from delivery services.

    Announcement of addition to new retail chains to Grabmart:

    Grab announced in November they are starting to add new retail chains to Grabmart to expand into grocery delivery services across Southeast Asia.

     Financial standings of Grab’s 3rd quarter:

    • According to 30 September 2021 data, Grab announced a loss of $988 million, last year the loss was $621 million.
    • Saw a decline of 9% in revenue.
    • Monthly Transacting User (MTUs) decline by 8$ due to the lockdowns. It should grow up as the situation normalizes.
    • Average spending per user was increased by 43%.
    • Grab had cash liquidity of $5.2 Billion which is $1.5 Billion more than 2020. In December 2020 Grab had cash liquidity of $3.7 billion.

    Conclusion:

    After the new announcement of the new partnership of Altimeter Growth Corp. (AGC) with Lazada, the share price of AGC is showing positive signs.

  • Securing a $250 million investment, Autolus Therapeutics plc (AUTL) becomes bullish Pre-Market

    After the previous close at $5.56 (-1.59%), AUTL stock becomes bullish, reaching $7.08 with a +27.34% increase in the Pre-Market on Monday, Nov. 8, 2021. Autolus Therapeutics published a press release on Nov. 8, announcing Blackstone Life Sciences to invest up to $250 million in AUTL for funding the development of a new treatment for a serious form of leukemia. $150 million out of the total investment will support the development and commercialization of cell therapy to target lymphoblastic leukemia. $50 million will be paid upfront to AUTL, while the rest to be paid upon the set milestones. Blackstone Life Sciences to receive a portion of the therapy’s royalties in return. Furthermore, Blackstone will also buy $100 million worth of AUTL’s American depository shares. The press release set the AUTL stocks on a bullish path.

    Autolus Therapeutics

    Autolus Therapeutics Plc is a UK-based biopharmaceutical company, specializing in the development and commercialization of gene therapies. The company is developing programmed T-cell therapies for the treatment of cancer with the clinical-stage product targeting hematological cancers like leukemia. Its products include AUT02, AUT03, AUT04, and AUT06, each being a T-cell therapy for targeting specific types of cancers.

    AUTL in the Numbers

    On November 3, 2021, AUTL released its third-quarter 2021 financial results and progress for the quarter ended September 30, 2021. As per the press release, compared to $216.4 million on June 30, 2021, the cash on September 30, totaled $173.1 million. The expenses for research and development decreased to $32.3 million in this quarter from $33.5 million in the previous quarter. Cash costs decreased to $29.4 million from $30.0 million while the non-cash costs decreased to $2.9 million for this quarter from $3.5 million in the previous. Moreover, the general and administrative expenses decreased to $8.3 million for this quarter from $9.8 million in the previous. Other income/expense increased by $3.5 million from $2.5 million of the previous quarter.

    A net loss of $34.0 million ($0.47 per ordinary share) was attributable to ordinary shareholders for the three months ended September 30, 2021, in comparison to $37.3 million ($0.72 per ordinary share) for the same period in 2020. According to their estimates, the current cash on hand will provide Autolus with a cash runway into H1 2023.

    Future Forecast of AUTL Stock

    According to CNN Business, 9 different analysts forecast AUTL to continue being bullish over the course of twelve months. According to the forecast, AUTL has a median target of $13.00, estimated going as high as $20.00 and as low as $5.50. Even the median estimate shows a huge increase from the current stock price of AUTL.

  • TDH Holdings, Inc. (PETZ) Takes A Dip But Will The Fall Continue?

    TDH Holdings, Inc. (PETZ) stock continues its fall in the premarket currently being at $3.80 while it was closed at $3.88 (i.e. -8.92%) on November 5, 2021. The company said Wednesday it raised approximately $9.9 million in gross proceeds by selling15,000,000 common shares priced at $0.64 per share and warrants $0.01 per warrant to purchase 30,000,000 common shares, with the warrants being exercisable at $1.47 per share. This announcement resulted in an aftermarket surge of 195.78% in the price of PETZ stocks. This dramatic bullishness of the stock leads to profit takers closing their profits and hence, starting the decline in the company’s stock price.

    More about TDH Holdings

    Founded in April 2002, TDH Holdings, Inc. is a PRC-based company specializing in the development, manufacturing, and sales of pet foods and products in China and beyond. The company offers 200 products, including various product lines like pet chews, dried pet snacks, wet canned food, dental health snacks, and baked pet biscuits.

    PETZ Earnings

    The company declared unfathomable financial results in April 2021 for the fiscal year 2020, showing a huge financial loss. The company’s revenues showed a decrease of 93.55% i.e. a meagre $0.82 million in the fiscal year 2020 from $12.65 million in the fiscal year 2019. The company attributed the decrease in total revenues mainly due to a decline in sales of products on part of uncompetitive sale prices making the products less attractive to the customers. PETZ also listed reasons like partial suspension of overseas E-commerce business because of estimated gross loss; suspension of production and operations due to defaults on loan repayments.

    Better cost management and halt on taking unprofitable orders resulted PETZ to decrease its gross loss i.e. $0.04 million gross loss in the fiscal year 2020 as compared to $1.52 million gross loss in the fiscal year 2019. Furthermore, the operating loss was $1.93 million for 2020 while it was $6.96 million in 2019. A net loss of $0.02 per share or $0.87 million was attributed to common stockholders as compared to a net loss of $0.41 per share or $8.63 million, for 2019.

    Will the fall in PETZ stock sustain?

    Previously the annual general meeting was supposed to be held on October 28, 2021, but later a postponement of the Annual General Meeting was announced, which is now to be held on December 28, 2021. While penny stocks like TDH Holdings are more volatile and have somewhat unclear movements as compared to the larger companies, the end of the fiscal year 2021 would be crucial to the future trajectory of the stock. While different analyst do suggest bullishness in PETZ stock for the long term, as it has been going up since its inception, the upcoming days will clarify whether or not the bearishness will sustain PETZ in near future.